Search research articles
Contact Us
Filters
Showing results (471-480 of 509) with videos related to
Page
of 51
Sort By:
The Lancet. Oncology
|
June 28, 2017
Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trial
William D Tap, Zsuzsanna Papai, Brian A Van Tine, et al.
Nature Communications
|
August 26, 2025
Maintenance olaparib after platinum-based chemotherapy for advanced/metastatic endometrial cancer: GINECO randomized phase IIb UTOLA trial
Florence Joly, Alexandra Leary, Isabelle Ray-Coquard, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
December 21, 2023
Updated progression-free survival and final overall survival with maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial
Domenica Lorusso, Marie-Ange Mouret-Reynier, Philipp Harter, et al.
Journal of the National Cancer Institute
|
April 25, 2026
Health-related quality of life in patients with newly diagnosed advanced ovarian cancer receiving maintenance olaparib plus bevacizumab (PAOLA-1/ENGOT-ov25)
Florence Joly, Amélie Anota, Sylvie Chabaud, et al.
The Lancet. Oncology
|
July 28, 2022
Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup
Ignace Vergote, Antonio Gonzalez-Martin, Domenica Lorusso, et al.
Journal for Immunotherapy of Cancer
|
February 19, 2026
Lenvatinib plus pembrolizumab in previously treated advanced endometrial cancer: 5-year outcomes from the randomized, phase 3 Study 309/KEYNOTE-775
Vicky Makker, Nicoletta Colombo, Antonio Casado, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
December 13, 2025
ESMO-ESTRO consensus statements on the safety of combining radiotherapy with CDK4/6, HER2, PARP, or mTOR inhibitors
Evert S M van Aken, Ajeet Kumar Gandhi, Sean M O'Cathail, et al.
Cell Reports. Medicine
|
December 20, 2023
GIInger predicts homologous recombination deficiency and patient response to PARPi treatment from shallow genomic profiles
Christian Pozzorini, Gregoire Andre, Tommaso Coletta, et al.
Cancers
|
July 14, 2023
Development of the NOGGO GIS v1 Assay, a Comprehensive Hybrid-Capture-Based NGS Assay for Therapeutic Stratification of Homologous Repair Deficiency Driven Tumors and Clinical Validation
Eva-Maria Willing, Claudia Vollbrecht, Christine Vössing, et al.
The Lancet. Oncology
|
August 9, 2016
Monogenic and polygenic determinants of sarcoma risk: an international genetic study
Mandy L Ballinger, David L Goode, Isabelle Ray-Coquard, et al.
Page
of 51
Search research articles
Search
Showing results (471-480 of 509) with videos related to
Sort By:
Page
of 51
The Lancet. Oncology
|
June 28, 2017
Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trial
William D Tap, Zsuzsanna Papai, Brian A Van Tine, et al.
Nature Communications
|
August 26, 2025
Maintenance olaparib after platinum-based chemotherapy for advanced/metastatic endometrial cancer: GINECO randomized phase IIb UTOLA trial
Florence Joly, Alexandra Leary, Isabelle Ray-Coquard, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
December 21, 2023
Updated progression-free survival and final overall survival with maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial
Domenica Lorusso, Marie-Ange Mouret-Reynier, Philipp Harter, et al.
Journal of the National Cancer Institute
|
April 25, 2026
Health-related quality of life in patients with newly diagnosed advanced ovarian cancer receiving maintenance olaparib plus bevacizumab (PAOLA-1/ENGOT-ov25)
Florence Joly, Amélie Anota, Sylvie Chabaud, et al.
The Lancet. Oncology
|
July 28, 2022
Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup
Ignace Vergote, Antonio Gonzalez-Martin, Domenica Lorusso, et al.
Journal for Immunotherapy of Cancer
|
February 19, 2026
Lenvatinib plus pembrolizumab in previously treated advanced endometrial cancer: 5-year outcomes from the randomized, phase 3 Study 309/KEYNOTE-775
Vicky Makker, Nicoletta Colombo, Antonio Casado, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
December 13, 2025
ESMO-ESTRO consensus statements on the safety of combining radiotherapy with CDK4/6, HER2, PARP, or mTOR inhibitors
Evert S M van Aken, Ajeet Kumar Gandhi, Sean M O'Cathail, et al.
Cell Reports. Medicine
|
December 20, 2023
GIInger predicts homologous recombination deficiency and patient response to PARPi treatment from shallow genomic profiles
Christian Pozzorini, Gregoire Andre, Tommaso Coletta, et al.
Cancers
|
July 14, 2023
Development of the NOGGO GIS v1 Assay, a Comprehensive Hybrid-Capture-Based NGS Assay for Therapeutic Stratification of Homologous Repair Deficiency Driven Tumors and Clinical Validation
Eva-Maria Willing, Claudia Vollbrecht, Christine Vössing, et al.
The Lancet. Oncology
|
August 9, 2016
Monogenic and polygenic determinants of sarcoma risk: an international genetic study
Mandy L Ballinger, David L Goode, Isabelle Ray-Coquard, et al.
Page
of 51